Stock Track | Absci Corporation Plummets 14.85% as Q3 Results Fall Short of Expectations

Stock Track11-13

Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 14.85% in pre-market trading, extending its losses following a 9.71% decline in the previous regular trading session. The significant drop comes in the wake of the company's disappointing third-quarter 2025 financial results, which were released on Wednesday and fell far short of analyst expectations.

The biotechnology company, which specializes in AI-powered drug discovery, reported alarmingly weak figures for Q3 2025. Absci's revenue plummeted to just $378,000, marking a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. While the company's earnings per share (EPS) of $(0.20) slightly beat expectations of $(0.21), it still indicated substantial losses. Absci's net loss for the quarter widened to $28.7 million, with operating expenses remaining high at $30.5 million.

Despite reporting some positive developments in its drug pipeline, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-202 in December, these advancements were not enough to offset investor concerns. The market's focus remained firmly on Absci's declining revenue and expanding losses, leading to the significant stock price decline in both regular trading and pre-market hours. Adding to the negative sentiment, Needham cut its target price for Absci from $8 to $7, further pressuring the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183617548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183617548","market":"sg","top_or_hot":-1,"title":"Stock Track | Absci Corporation Plummets 14.85% as Q3 Results Fall Short of Expectations","media":"Stock Track","content":"<p>Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 14.85% in pre-market trading, extending its losses following a 9.71% decline in the previous regular trading session. The significant drop comes in the wake of the company's disappointing third-quarter 2025 financial results, which were released on Wednesday and fell far short of analyst expectations.</p>\n\n<p>The biotechnology company, which specializes in AI-powered drug discovery, reported alarmingly weak figures for Q3 2025. Absci's revenue plummeted to just $378,000, marking a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. While the company's earnings per share (EPS) of $(0.20) slightly beat expectations of $(0.21), it still indicated substantial losses. Absci's net loss for the quarter widened to $28.7 million, with operating expenses remaining high at $30.5 million.</p>\n\n<p>Despite reporting some positive developments in its drug pipeline, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-202 in December, these advancements were not enough to offset investor concerns. The market's focus remained firmly on Absci's declining revenue and expanding losses, leading to the significant stock price decline in both regular trading and pre-market hours. Adding to the negative sentiment, Needham cut its target price for Absci from $8 to $7, further pressuring the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Absci Corporation Plummets 14.85% as Q3 Results Fall Short of Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Absci Corporation Plummets 14.85% as Q3 Results Fall Short of Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 14.85% in pre-market trading, extending its losses following a 9.71% decline in the previous regular trading session. The significant drop comes in the wake of the company's disappointing third-quarter 2025 financial results, which were released on Wednesday and fell far short of analyst expectations.</p>\n\n<p>The biotechnology company, which specializes in AI-powered drug discovery, reported alarmingly weak figures for Q3 2025. Absci's revenue plummeted to just $378,000, marking a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. While the company's earnings per share (EPS) of $(0.20) slightly beat expectations of $(0.21), it still indicated substantial losses. Absci's net loss for the quarter widened to $28.7 million, with operating expenses remaining high at $30.5 million.</p>\n\n<p>Despite reporting some positive developments in its drug pipeline, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-202 in December, these advancements were not enough to offset investor concerns. The market's focus remained firmly on Absci's declining revenue and expanding losses, leading to the significant stock price decline in both regular trading and pre-market hours. Adding to the negative sentiment, Needham cut its target price for Absci from $8 to $7, further pressuring the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABSI","symbol_name":"Absci Corporation.","start_time":0,"source_url":"","article_id":"1183617548","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183617548","pubTimestamp":1763044511,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 14.85% in pre-market trading, extending its losses following a 9.71% decline in the previous regular trading session. The significant drop...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABSI":"Absci Corporation."},"translate_title":"个股追踪|Absci Corporation暴跌14.85%因Q3业绩不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":1},"content_text":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 14.85% in pre-market trading, extending its losses following a 9.71% decline in the previous regular trading session. The significant drop comes in the wake of the company's disappointing third-quarter 2025 financial results, which were released on Wednesday and fell far short of analyst expectations.\nThe biotechnology company, which specializes in AI-powered drug discovery, reported alarmingly weak figures for Q3 2025. Absci's revenue plummeted to just $378,000, marking a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. While the company's earnings per share (EPS) of $(0.20) slightly beat expectations of $(0.21), it still indicated substantial losses. Absci's net loss for the quarter widened to $28.7 million, with operating expenses remaining high at $30.5 million.\nDespite reporting some positive developments in its drug pipeline, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-202 in December, these advancements were not enough to offset investor concerns. The market's focus remained firmly on Absci's declining revenue and expanding losses, leading to the significant stock price decline in both regular trading and pre-market hours. Adding to the negative sentiment, Needham cut its target price for Absci from $8 to $7, further pressuring the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183617548","isCrawlerRequest":true}